Corvus Pharmaceuticals Inc <CRVS.OQ> expected to post a loss of 12 cents a share - Earnings Preview
Corvus Pharmaceuticals Inc CRVS.OQ CRVS.O is expected to show no change in quarterly revenue when it reports results on March 25 for the period ending December 31 2024
LSEG's mean analyst estimate for Corvus Pharmaceuticals Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc is $13.00, above its last closing price of $4.21.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.11 | -0.12 | -0.60 | Missed | -414.6 |
Jun. 30 2024 | -0.12 | -0.11 | -0.04 | Beat | 65.2 |
Mar. 31 2024 | -0.14 | -0.12 | -0.12 | Met | 0 |
Dec. 31 2023 | -0.12 | -0.14 | Missed | -17.6 | |
Sep. 30 2023 | -0.12 | -0.12 | -0.12 | Met | 1.6 |
Jun. 30 2023 | -0.16 | -0.14 | -0.14 | Met | -0.5 |
Mar. 31 2023 | -0.16 | -0.16 | -0.17 | Missed | -8.3 |
Dec. 31 2022 | -0.25 | -0.23 | -0.21 | Beat | 9.1 |
This summary was machine generated March 21 at 20:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recommended Articles
